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1684-1182/Copyright ª 2014, Taiwan S
BY-NC-ND license (http://creativecomKawasaki disease (KD) is a systemic vasculitis of unknown etiology and it is therefore worth
examining the multifactorial interaction of genes and environmental factors. Targeted genetic
association and genome-wide association studies have helped to provide a better understand-
ing of KD from infection to the immune-related response. Findings in the past decade have
contributed to a major breakthrough in the genetics of KD, with the identification of several
genomic regions linked to the pathogenesis of KD, including ITPKC, CD40, BLK, and FCGR2A.
This review focuses on the factors associated with the genetic polymorphisms of KD and the
pharmacogenomics of the response to treatment in patients with intravenous immunoglobulin
resistance.
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Table 1 “Kuo mnemonic” for the rapid memorization of
the diagnostic criteria for Kawasaki disease
Number Mnemonic Clinical signs
1 “One” mouth Diffuse mucosal inflammation
with strawberry tongue and
fissure lips







4 “Four” limbs e
changes
Indurative angioedema
over both hands and feet
5 “Five” Z multiple
skin rash
Dysmorphic skin rash
2 H.-C. Kuo et al.Introduction
Kawasaki disease (KD) is a pediatric disease characterized
as an acute systemic vasculitis syndrome. It was first re-
ported in Japanese by Kawasaki et al1 in 1967 and in English
in 1974 and is currently thought to be the primary cause of
acquired heart disease of children in industrialized coun-
tries. KD predominantly affects the coronary arteries and
causes coronary artery lesions (CALs). The symptoms of KD
are myocardial infarction, coronary artery fistulas, coro-
nary artery aneurysms, and coronary artery dilatation,
which can develop long-term sequelae, e.g., stenosis or
obstruction.2 Several genes, including ITPKC, TGFBR2,
CASP3, COL11A2, and SRC-1, have been considered as being
associated with the formation of CALs in KD.3e7 However, to
date, the etiology of KD remains unknown.8e10 KD has a
predilection for children younger than 5 years and epide-
miology records have shown that Asian countries (especially
Japan, Taiwan, and Korea) have a higher incidence rate
than Western countries. In addition, the incidence rate is
increasing worldwide, except in Taiwan.11,12
The etiology of KD may be attributed to the combined
effects of infection, immune response, tropospheric winds,
and genetic susceptibility.13e22 The standard treatmentwith
high doses of aspirin (80e100 mg/kg/day) and high doses of
intravenous immunoglobulin (IVIG, 2 g/kg) has been shown
to significantly decrease the rate of formation of coronary
artery aneurysms from 20e25% to 3e5%.23,24 Newburger
et al94 first reported that in the treatment of children with
the acute stage of KD, the use of a single large dose of IVIG is
more effective than the conventional four-dose or two-dose
regimen. Burns et al9 have also mentioned that a large and
single dose of IVIG is now the gold standard treatment in KD.
However, the effectiveness of IVIG in KD remains under
investigation and FCGR2A may be worth considering based
on genome-wide association studies.
The clinical characteristics of patients with KD include
fever lasting for more than 5 days, diffuse mucosal
inflammation with strawberry tongue and fissure lips,
bilateral nonpurulent conjunctivitis, indurative angioe-
dema over the hands and feet, dysmorphic skin rashes, and
unilateral cervical lymphadenopathy. We have established
the “Kuo mnemonic” for rapid memorization of the diag-
nostic criteria of KD (Table 1).
Treatment with IVIG
IVIG has been used for the treatment of KD since it was first
reported by Furusho et al25 in 1983, > 10 years after the first
report of KD. A randomized controlled trial by Newburger
et al26 in 1986 showed that high doses of IVIG (400 mg/kg/
d for 4 days) were safe and effective in reducing the prev-
alence of CALs from 20e25% to 3e5% when administered to
patients with acute KD. In regard to the correct dose of IVIG,
Newburger et al suggested in 1991 that a single high dose of
IVIG (2 g/kg) is more effective than a 4-day regimen.
Currently, a large and single dose of IVIG is considered to be
the gold standard in the treatment of patients with KD in the
acute phase.94 Nevertheless, its mechanism for decreasing
inflammation in KD remains unclear and requires investiga-
tion. It is suspected that the related mechanisms mayinclude blockade of the Fc receptor,16,27 neutralization of
the pathogenic or toxic products of an unknown infectious
agent, an immune-modulatory effect,28 stimulation of sup-
pressor activity, and modulation of cytokines and cytokine
antagonists.29
IVIG appears to have a generalized anti-inflammatory
effect. Possible mechanisms include the enhancement of
regulatory T cell activity (transforming growth factor),
neutralization of bacterial super-antigens or other unknown
pathogenic agents, regulation of cytokine production,
suppression of antibody synthesis and inflammatory
markers (CD40eCD40L, nitric oxide, and inducible nitric
oxide synthase expression),17,18,30,31 the provision of anti-
idiotypic antibodies, the Fc-gamma receptor and inter-
leukin 1b, and balancing the T helper (Th) Th1/Th2 immune
responses.30e37
For patients with KD, treatment with IVIG should be
performed within 10 days of the onset of the illness.
Existing data have shown that receiving treatment prior to
Day 5 of the onset of illness appears to be no more likely to
prevent cardiac sequelae than treatment on Days 5e9.2,9,10
However, this phenomenon may, for unknown reasons, be
associated with an increased need for retreatment with
IVIG.
The efficacy of receiving IVIG treatment after 10 days of
illness has not been well studied. Therefore we suggest that
both early diagnosis and treatment are essential (within 10
days of the onset of illness). Patients with KD with incom-
plete treatment or delayed diagnosis should still be given
IVIG. For example, children who develop symptoms such as
persistent and systemic inflammation, continuous fever of
unknown origin, the formation of aneurysms, and high
concentrations of inflammatory markers as manifested by
an increased erythrocyte sedimentation rate or C-reactive
protein (with or without coronary artery abnormalities)
should receive IVIG treatment even if the diagnosis is made
after 10 days of the illness (i.e., delayed diagnosis). For
IVIG-resistant patients who have a higher risk of developing
CALs than IVIG-sensitive patients, earlier and highly effec-
tive anti-inflammatory treatment must be emphasized to
reduce the risk of forming CALs. Infliximab has been shown
to be effective in IVIG resistance; however, combining
infliximab with the standard treatment in acute KD did not
reduce resistance to treatment.38,39
Table 2 Clinical characteristics in Kawasaki disease
related to intravenous immunoglobulin resistance
Factor High-risk group of
IVIG resistance
Refs










Treatment day Day 4 or earlier; before





Onset of Kawasaki disease
more than twice
72
Brand of IVIG IVIG product prepared with
beta-propiolactone
40,41
IVIG Z intravenous immunoglobulin.
Pharmacogenomics of Kawasaki disease 3The American Academy of Pediatrics and the American
Heart Association have published treatment guidelines
suggesting rapid treatment with a combination of high
doses of immunoglobulins (2 g/kg) within 8e12 h and high
doses of aspirin as the standard treatment for KD.2 Immu-
noglobulins are obtained from human blood; however,
although the World Health Organization has published
production guidelines, there are some differences in the
manufacturing processes that may affect the efficiency of
treatment, such as purification, immunoglobulinA concen-
trations, and conditions related to preservation.40 The as-
sociation between preservation conditions and the
effectiveness of treatment have also been studied. Tsai
et al41 reported that b-propiolactonation is related to the
promotion of the rate of failure of the initial IVIG treat-
ment. However, in a retrospective study of the existing
Canadian data, Manlhiot et al42 found a contradictory
result, which noted that preserving immunoglobulins in
acidic conditions led to a lower treatment failure rate, but
increased the rate of coronary aneurysms. Lin et al40
reached a similar conclusion, stating that b-propiolacto-
nation in IVIG preparation resulted in an increased risk of
treatment failure and prolonged use of antiplatelet or
anticoagulant treatment. Acidification might have induced
the formation of acute coronary aneurysms in the 3830
children enrolled in a population-based study in Taiwan.Table 3 Laboratory data related to intravenous immu-
noglobulin resistance in Kawasaki disease
Factor High-risk group of
IVIG resistance
Refs
Albumin Albumin <2.9 g/dL 49,51,76,79e81
Sodium 133 mmol/L 71,79
Eosinophils Increase in eosinophils
indicates responsiveness
50
Platelet count 30.0  104/mm3 70,71,82
Hemoglobin Anemia by age 43,81
Neutrophils 75% 70,74,76,81e84
Band form Increased 43,80,81
CRP 10 mg/dL 43,70,71,73,74,76,84
Liver enzymes ALT  84 IU/L,
AST  100 IU/L, total





ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; CRP Z C-reactive protein; ESR Z erythrocyte
sedimentation rate; IVIG Z intravenous immunoglobulin; NT-
BNP Z N-terminal fragment of B-type natriuretic peptide; PT/
INR Z prothrombin time international normalized ratio.IVIG resistance
Tremoulet et al43 reported that the incidence of IVIG
resistance ranged from 9.4% to 23% among hospitals and
countries generally, but the highest percentage of IVIG-
resistant patients reached 38%. As IVIG-resistant patients
have a higher probability for CAL formation, it is important
to treat them aggressively. There are several treatments
available to combine with the second administration of IVIG
for patients who do not respond to the initial IVIG treat-
ment, such as tumor necrosis factor a (TNF-a) blockade,39
methylprednisolone pulse treatment,44 cytotoxic drugs
(cyclophosphamide, cyclosporine A, and methotrexate45),
plasmapheresis,46 and plasma exchange.47
Tables 2 and 3 show that recent studies have identified a
number of epidemiological and laboratory characteristics
as predictors of IVIG resistance,40,41,43,49e51,70e85 with bio-
markers including age, illness day, platelet count, eryth-
rocyte sedimentation rate, hemoglobin concentration,
C-reactive protein, eosinophils, lactate dehydrogenase,
albumin, alanine aminotransferase, clusterin, G-CSF, and
sonographic gallbladder abnormalities.48e53
The plasma concentrations of TNF and soluble TNF re-
ceptors are increased in acute KD and are associated with
the formation of CALs.54 TNF-a is also reported to be
necessary to incite the inflammation of coronary arteries
and for the formation of aneurysms in an animal model of
KD.55 Some studies using infliximab or etanercept in pa-
tients resistant to an initial intravenous immunoglobulin
treatment have been suggested as having some benefit.38,56
TNF-a blockade has been shown to be beneficial in patients
with KD with IVIG resistance, but this is not recommended
as a primary treatment with IVIG. Although there is evi-
dence to show that there are biomarkers associated withIVIG resistance, the accurate prediction of potentially IVIG-
resistant patients and application of an aggressive treat-
ment regimen remains a challenge for both clinicians and
scientists. For patients with severe KD or for those in a high-
risk group, Kobayashi et al57 suggested that the addition of
prednisolone to the standard regimen of IVIG could improve
coronary artery outcomes.
Aspirin
Aspirin has been prescribed as a treatment for KD for many
years, even before IVIG was used. Although aspirin has
Table 4 IVIG resistance-related cytokines in Kawasaki
disease
Factor High-risk group of
IVIG resistance
Refs
Clusterin Post-IVIG e pre-IVIG >8.52 mg/L 53
IL-6 Pre-IVIG, 70 pg/mL IL-6
level <140 pg/mL
84
IL-10 Post-IVIG, >10 pg/mL 28
TNF-a Post-IVIG, <2 pg/ mL 28
IL-17 Higher expression 86
CD4 þ CD25 þ
FoxP3 Treg
Higher expression frequency 86
NT-proBNP >800 pg/mL 87
G-CSF Higher expression 88
G-CSF Z granulocyte colony-stimulating factor;
IVIG Z intravenous immunoglobulin; IL Z interleukin; NT-
proBNP Z N-terminal fragment of pro-B-type natriuretic pep-
tide; TNF Z tumor necrosis factor.
4 H.-C. Kuo et al.important anti-inflammatory (at high doses) and anti-
platelet (at low doses, 3e5 mg/kg/day) effects, it does not
appear to reduce the frequency of CAL formation and IVIG
resistance in patients with KD. The integration of anti-
inflammatory doses of aspirin with IVIG has been suggested,
but the doses remain controversial. High doses of aspirin
(80e100 mg/kg/d) are most widely applied in North
America during the acute stage, whereas moderate doses
(30e50 mg/kg/d) are recommended as a standard treat-
ment in Japan.
However, a report has indicated that combining aspirin
with the standard treatment in the acute stage of KD does
not affect the IVIG response rate, continuing fever, nor CAL
formation.58 To date, the existing data show no benefit to
patients in the acute phase of KD and thus treatment with
high or medium doses of aspirin may not be necessary.
Reye’s syndrome is a potentially fatal syndrome; it is
largely seen in children who are treated with salicylates
while experiencing infection with a virus. Reye’s syndrome
has been reported in patients using high doses of aspirin for
a long period of time after KD.59 Although there is no
proven causal link, some studies have shown an association
between aspirin use and Reye’s syndrome. Aspirin use in
children should be limited to diseases with a clearly proven
benefit, such as KD and juvenile idiopathic arthritis.60 Hsieh
et al58 have reported that treatment without high doses of
aspirin did not affect the response rate of IVIG treatment,
fever duration, nor incidence of CAL for patients in the
acute phase compared with children who were treated with
high doses of IVIG as a single infusion. Chen et al61 reported
that patients with KD with glucose-6-phosphate dehydro-
genase deficiency who did not receive aspirin during
treatment had a good response without CAL complications.
Whether high doses of aspirin should be given in the acute
stage of KD or not warrants further multi-center random-
ized control trials before a definitive recommendation can
be made.Table 5 Genetic variants in Kawasaki disease related to
intravenous immunoglobulin resistance
Factor High-risk group of
IVIG resistance
Refs
ITPKC rs28493229 C allele 68,69,89
CASP3 rs113420705 A allele 68,69,89
FCGR2A rs1801274 A allele 89
DC-SIGN (CD209) rs4804803 G allele,
rs2287886 A allele
90,91
CCR2-CCR5 HHF*2 haplotype 92
CCL3L1 <4 copies 92
IL-1B 511 TT genotype,
31 CC genotype
93
PAF-AH V279F GG genotype 73
CASP3Z caspase 3; CCL3L1Z chemokine (C-C motif) ligand 3-
like 1; CCR2 Z CC chemokine receptor 2; CCR5 Z CC chemo-
kine receptor 5; DC-SIGN Z dendritic cell-specific intercellular
adhesion molecule-3-grabbing nonintegrin; FCGR2A Z Fc frag-
ment of immunoglobulin G, low affinity IIa, receptor;
IVIG Z intravenous immunoglobulin; ITPKC Z inositol 1,4,5-
trisphosphate 3-kinase C; PAF-AH Z platelet-activating factor
acetylhydrolase.Biomarkers, pharmacogenomics, and IVIG
treatment
Several biomarkers and genetic polymorphisms have been
reported to predict IVIG resistance (Table 4).28,53,84,86e88
Based on their work on T cell markers, Hirabayashi et al62
have indicated that a lower percentage of CD4(þ)CD25(þ)
FOXP3(þ) regulatory T cells was observed in the peripheral
blood of patients with KD. Furthermore, the study showed
that IVIG resistance was related to a lack of CD4(þ)CD25(þ)
FOXP3(þ) regulatory T cells. FOXP3 was also reported to
play an important part in the development of breast cancer
and had implications for treatment and diagnosis.63
Brain natriuretic peptide (BNP), a cardiac hormone
secreted by the ventricle, has been proposed as a marker of
the acute phase of KD. The concentrations of BNP have
been found to increase in plasma during the acute stage
and then decrease to within the normal range in the
convalescent stage of KD.64 NT-proBNP, the N-terminal
fragment of BNP, increases in the acute phase, but de-
creases in the convalescent phase of KD. Kim et al65 indi-
cated that a higher level of serum NT-proBNP was
associated with IVIG resistance in patients with KD. An NT-proBNP level 1093 pg/dL might be a potential predictor of
the failure of IVIG treatment. In addition, genetic varia-
tions were associated with IVIG resistance in patients with
KD. In 2011, Shrestha et al66 showed that the TT genotype
of the FcgRIIB (120T/a) gene showed a significant asso-
ciation with unresponsiveness to IVIG in patients with KD.
Gene copy number and polymorphism of FcgR influences of
the IVIG treatment response and in the susceptibility of KD
were reported, providing potential insights into under-
standing the mechanism of the FcgR gene family in the IVIG
pathway.27,67 The fragment crystallizable (Fc) region links
the key pathogen identification and destruction properties
of immunoglobulin G. Pathogen opsonization positions Fcs
to activate proinflammatory Fcg receptors on immune
Pharmacogenomics of Kawasaki disease 5cells. The expression of Fcg receptors and the association
between receptors and genetic polymorphism and epige-
netic effects are needed to clarify the role of Fcg receptors
in KD and the IVIG treatment response. The Fc domain or
other Fc fragment may be more effective in the treatment
of KD than IVIG; further studies are needed.
The C allele of ITPKC (rs28493229) and the A allele of
CASP3 (rs113420705) were associated with susceptibility to
KD and CAL formation, but not to the IVIG treatment
response.5,14,15,33 A combination of ITPKC (rs28493229) and
CASP3 (rs113420705) polymorphisms affected the IVIG
treatment response and the risk of CAL formation.68,69
Table 5 shows the IVIG resistance-related genetic variants
in KD.68,69,73,89e93
As high-throughput genomic technology and genomic
information become more readily available, further
insightful research is expected to better elucidate the
markers responsible for the response to IVIG treatment in
patients with KD.
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